NASDAQ:KALA KALA BIO Q4 2025 Earnings Results & Report $0.28 -0.01 (-4.76%) Closing price 10/12/2026 04:00 PM EasternExtended Trading$0.28 +0.00 (+0.71%) As of 10/12/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. KALA BIO beat analyst earnings expectations in its Q4 2025 results, released April 15, 2026. The company reported EPS of $0.86 versus the -$8.50 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateApril 15, 2026TimeBefore Market OpensConference Call7:00 AM ET KALA BIO EPS ResultsActual EPS$0.86Consensus EPS -$8.50Beat/MissBeat by +$9.36One Year Ago EPSN/AEPS Beat Rate3 of last 5 quartersKALA BIO Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsKALA BIO's Q3 2026 earnings is estimated for Tuesday, November 10, 2026, based on past reporting schedulesConference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) KALA BIO Q4 2025 Earnings FAQ Did KALA BIO beat earnings estimates for Q4 2025? KALA BIO (NASDAQ:KALA) reported earnings of $0.86 per share for Q4 2025, beating the consensus estimate of -$8.50. The report was announced on Wednesday, April 15, 2026. When is KALA BIO's next earnings date? KALA BIO's next earnings date is estimated for Tuesday, November 10, 2026. MarketBeat tracks confirmed and estimated earnings dates for KALA BIO on the company's earnings history page. KALA BIO Earnings HeadlinesKALA BIO, Inc. (NASDAQ:KALA) Stock Short Interest Report for SeptemberOctober 12 at 5:20 AM | americanbankingnews.comKALA Bio Signs LOI To Acquire Nationwide Telehealth Platform; Shares RiseSeptember 30, 2026 | rttnews.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now. | Stansberry Research (Ad)Kala Bio, Inc. And Virotek Inc. Sign Letter Of Intent With U.S. DNA Testing Platform To Resell Virotek Inc.'s Suite Of Genetic Testing ProductsSeptember 25, 2026 | marketscreener.comMKala Bio, Inc. und Virotek Inc. unterzeichnen Absichtserklärung mit einer US-amerikanischen DNA-Testplattform zum Weiterverkauf der genetischen Testproduktpalette von Virotek Inc.September 25, 2026 | de.marketscreener.comDKala Bio And Virotek Sign LOI To Expand Genetic Testing DistributionSeptember 24, 2026 | rttnews.comSee More KALA BIO Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like KALA BIO? Sign up for Earnings360's daily newsletter to receive timely earnings updates on KALA BIO and other key companies, straight to your email. Email Address About KALA BIOKALA BIO (NASDAQ:KALA), formerly known as Kala Pharmaceuticals, is a clinical-stage biotechnology company focused on developing treatments for severe diseases affecting the eye. The company’s research has centered on therapies designed to address conditions for which available treatment options may be limited or inadequate. KALA BIO’s lead investigational product has been KPI-012, an ophthalmic biologic being studied for rare corneal conditions, including persistent corneal epithelial defects. The company has also developed therapies using its proprietary mucus-penetrating particle technology, which is intended to improve the delivery of medicines to ocular tissues. Historically, the company developed and commercialized EYSUVIS, a corticosteroid eye drop approved in the United States for the short-term treatment of dry-eye disease, and XIPERE, an injectable treatment for macular edema associated with uveitis. KALA BIO is headquartered in the United States and has primarily focused its development and regulatory activities on the U.S. ophthalmology market.View KALA BIO ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Retail Picks to Watch as the Holiday Shopping Season NearsMarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsC.H. Robinson Bets Its AI Story on RXO—But the Market Isn't SoldApplied Digital’s Hidden Moat Could Unlock Massive Upside Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
